Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials

Eikon Therapeutics’ IPO haul will support a lead program that could expand the scope of cancer immunotherapy. Eikon’s stock market debut builds on growing IPO momentum, following upsized offerings from Aktis Oncology and Veradermics. The post Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials appeared first on MedCity News.

Read More

The Return of American Manufacturing Demands a Chief Health & Benefits Officer (CHBO) to Fix Benefits Procurement

By MATT McCORD American manufacturing is making a comeback. Driven by tariffs, supply chain instability, and shifting economic priorities, companies are reshoring production—reinvesting in U.S. labor and operations. But there’s one major obstacle still standing in the way: the crushing cost of American healthcare. For decades, U.S. employers have overpaid for healthcare without improving outcomes….

Read More